Scholarlink

<p>Alcoholic liver disease (ALD) is a major global public health concern. Although <i>Ganoderma lucidum</i> triterpenoid-enriched extract (GLE) possesses notable hepatoprotective potential, its inherent hydrophobicity and poor oral bioavailability have limited its clinical application. In this study, a lactobionic acid-modified zein/sodium alginate nanoplatform (LA-GL/ZSNPs) was engineered for enhanced liver delivery of GLE. The LA-GL/ZSNPs were successfully fabricated through hydrophobic core loading, hydrogen bond-mediated stabilization, and surface modification with lactobionic acid, yielding uniform spherical nanoparticles with excellent physicochemical stability, pH-responsive release behavior, and sustained-release properties. LA-GL/ZSNPs exhibited enhanced liver accumulation in vivo, showing a 71.07% higher hepatic accumulation than free GLE70 within 24 h. In a mouse model of ALD, oral administration of LA-GL/ZSNPs significantly alleviated hepatocellular injury, oxidative stress, and inflammation, while restoring lipid metabolism. Moreover, this modulated gut microbiota composition, increasing the relative abundances of <i>Lactobacillus</i>, <i>Prevotella</i>, and <i>Akkermansia</i>. This study introduces an oral nanoplatform that integrates enhanced hepatic accumulation with controlled-release functionality for the treatment of ALD.</p><p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Lactobionic acid-modified zein/sodium alginate nanoparticles for oral delivery of Ganoderma lucidum triterpenoids in alcoholic liver disease

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年8月5日

查看全文
  • Yanjun Chen,
  • Wenjia Li,
  • Jiayue Song,
  • Xinyu Hou,
  • Xiaobing Song,
  • Qianli Ma,
  • Quanliang Li,
  • Ping Chen

摘要

Alcoholic liver disease (ALD) is a major global public health concern. Although Ganoderma lucidum triterpenoid-enriched extract (GLE) possesses notable hepatoprotective potential, its inherent hydrophobicity and poor oral bioavailability have limited its clinical application. In this study, a lactobionic acid-modified zein/sodium alginate nanoplatform (LA-GL/ZSNPs) was engineered for enhanced liver delivery of GLE. The LA-GL/ZSNPs were successfully fabricated through hydrophobic core loading, hydrogen bond-mediated stabilization, and surface modification with lactobionic acid, yielding uniform spherical nanoparticles with excellent physicochemical stability, pH-responsive release behavior, and sustained-release properties. LA-GL/ZSNPs exhibited enhanced liver accumulation in vivo, showing a 71.07% higher hepatic accumulation than free GLE70 within 24 h. In a mouse model of ALD, oral administration of LA-GL/ZSNPs significantly alleviated hepatocellular injury, oxidative stress, and inflammation, while restoring lipid metabolism. Moreover, this modulated gut microbiota composition, increasing the relative abundances of Lactobacillus, Prevotella, and Akkermansia. This study introduces an oral nanoplatform that integrates enhanced hepatic accumulation with controlled-release functionality for the treatment of ALD.